[PDF] Top 20 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Has 10000 "Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" found on our website. Below are the top 20 most common "Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... of bone (incidence: ...accounts for >10% of all solid ...long bone, most commonly around the ...skeleton and craniofacial bones is primarily observed in ...accounts for 80%–90% of ... Voir le document complet
10
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
... the follow-up of melan- oma patients [ 53 ], if any blood test is recommended at all [IV, ...These clinical practice guidelines were developed in accordance with the ESMO ... Voir le document complet
7
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of soft tissue sarcomas
... Minimum Clinical Recommendations for diagnosis, treatment and follow-up of soft tissue sarcomas Incidence ... Voir le document complet
2
Ewing's sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
... of bone is the second most common primary malignant bone cancer in children and adolescents, but is also seen in adults, particularly the extraskeletal ...at diagnosis is 15 years and ... Voir le document complet
3
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... pleural and pericardial effusion, efforts should be made to obtain a cytological or histological confirmation of stage IV ...PET and, if needed for decision-making, invasive mediastinal node ... Voir le document complet
9
Ewing's sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
... of follow-up; late relapses have rarely been observed even after 15 years or ...of treatment are the main concern in long-term ...in follow-up, but cardiac or pulmonary damage may ... Voir le document complet
2
Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment andfollow-up
... Head and Neck Surgery, Centre Oscar Lambret, Lille, France; 4 Medical Oncology Head and Neck Unit, Istituto Nazionale dei Tumori, Milan, Italy; 5 Medical Oncology Service, Vall d’Hebron University Hospital, ... Voir le document complet
3
Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... a diagnosis of AML, MDSs remain a considerable diagnostic challenge, particularly in cases where blast counts are not increased in the bone marrow, and morphological findings are ...criteria ... Voir le document complet
4
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... initial treatment of patients with advanced ovarian ...disease and diminish development of subsequent drug ...patients and demonstrated that each 10% increase in the number of patients receiving ... Voir le document complet
8
Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
... megakaryocytic and mast cell lineage. The percentage of blast cells in the bone marrow is a practical tool for categorising myeloid neoplasms into AML or myelodysplastic syndromes (MDS), ... Voir le document complet
6
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... contraindications for the use of chemotherapy or anti-HER2 ...‘screening’ for metastatic disease in asymptomatic ...control) and less invasive loco-regional techniques, such as radiosurgery ... Voir le document complet
5
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for use in combination with paclitaxel as first-line treatment of MBC after showing a benefit of 6 months in PFS in ... Voir le document complet
6
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
... The optimal chemotherapy regimen has not been investigated in randomised studies which were specifically designed for this purpose. In the absence of such trials, no strict recommendation can be given as to the ... Voir le document complet
10
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up
... Mediastinoscopy and video-assisted thoracoscopy may be useful in determining ...system for MPM emphasizes the extent of disease post surgery in a traditional TNM system and stratifies patients into ... Voir le document complet
2
Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
... chemoradiotherapy and chemotherapy after resection of pancreatic ...survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized ... Voir le document complet
2
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment andfollow-up †
... count and LDH at 3, 6, 12, and 24 months, then only as needed for evaluation of suspicious symptoms or clinical findings in those patients suitable for further therapy [V, ...12, ... Voir le document complet
5
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
... function and corticosteroid use (Macdonald ...alive and progression free at 6 months (PFS6mo) has been recognized as a valid endpoint and also includes patients who benefit from therapy by disease ... Voir le document complet
3
Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
... upfront, and for which exact time ...shown for anastrozole (1 mg daily for 5 years) and for letrozole ...daily for 5 years) given upfront [I, A], for exemestane (25 ... Voir le document complet
4
Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
... size and site of ...adjuvant treatment with the drug has been ...dosed for 1 year in planned duration is able to prolong early relapse-free survival in completely resected >3 cm localized ... Voir le document complet
4
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
... criteria for phase II studies of supratentorial malignant ...lomustine and vincristine in the adjuvant treatment of high-grade astrocytomaa Medical Research Council ... Voir le document complet
3
Sujets connexes